Revenue (Details Textual) - USD ($) $ in Thousands |
1 Months Ended | 6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Nov. 01, 2022 |
Aug. 31, 2022 |
Jun. 30, 2026 |
Dec. 31, 2023 |
Dec. 31, 2025 |
|
| Revenue [Line Items] | |||||
| Deferred revenue | $ 6,276 | $ 8,246 | |||
| Revenue recognized | (5,020) | ||||
| BARDA [Member] | |||||
| Revenue [Line Items] | |||||
| Total grant revenue | $ 63,200 | ||||
| Grant revenue outstanding | 24,600 | ||||
| Gates Foundation [Member] | Grant Revenue [Member] | |||||
| Revenue [Line Items] | |||||
| Deferred revenue | 1,100 | ||||
| Research Collaboration And License Agreement [Member] | Seqirus Inc [Member] | |||||
| Revenue [Line Items] | |||||
| Upfront payment received | $ 200,000 | ||||
| CSL Collaboration Agreement [Member] | |||||
| Revenue [Line Items] | |||||
| Deferred revenue | $ 5,200 | $ 6,200 | |||
| CSL Collaboration Agreement [Member] | Phase I Clinical Study [Member] | |||||
| Revenue [Line Items] | |||||
| Milestone payments | $ 17,500 |